The prediagnostic phase of Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 8, 2016, Pages 871-878

  Noyce, Alastair John ^a   Lees, Andrew John ^a   Schrag, Anette Eleonore ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

EPIDEMIOLOGY; MOVEMENT DISORDERS; Parkinson'S DISEASE

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALCOHOL; ALPHA SYNUCLEIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CAFFEINE; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; PESTICIDE; SOMATOMEDIN C; TAU PROTEIN; UNCLASSIFIED DRUG; URIC ACID;

ANOSMIA; ANXIETY; BLOOD; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONSTIPATION; DEPRESSION; DISEASE CLASSIFICATION; DRINKING BEHAVIOR; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GBA GENE; GENE; GENE MUTATION; HEAD INJURY; HEREDITY; HUMAN; INFLAMMATION; INTESTINE; LIFESTYLE; LRRK2 GENE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SALIVA; SALIVARY GLAND; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN; SMOKING; SNCA GENE; STAGING; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; EARLY DIAGNOSIS; METABOLISM; PRODROMAL SYMPTOM;

BIOMARKERS; EARLY DIAGNOSIS; HUMANS; NEUROIMAGING; PARKINSON DISEASE; PRODROMAL SYMPTOMS; RISK FACTORS;

EID: 84962917512     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-311890     Document Type: Review

References (60)

1. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012;72:893-901.
2. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011;26:1049-55.
3. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 2013;28:14-23.
4. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
5. Peelaerts W, Bousset L, Van der Perren A, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015;522:340-4.
6. McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and Braak hypothesis. Mov Disord. Published Online First: 4 Sep 2015. doi10.1002/mds.26421
7. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-90.
8. Marras C, Schüle B, Schuele B, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011;77:325-33.
9. Nandhagopal R, McKeown MJ, Stoessl AJ. Functional imaging in Parkinson disease. Neurology 2008;70(16 Pt 2):1478-88.
10. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-61.
11. Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013;136:392-9.
12. Beavan M, McNeill A, Proukakis C, et al. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 2015;72:201-8.
13. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46:989-93.
14. Escott-Price V, Nalls MA, Morris HR, et al., International Parkinson's Disease Genomics Consortium. Polygenic risk of Parkinson disease is correlated with disease age at onset. Ann Neurol 2015;77:582-91.
15. Nalls MA, McLean CY, Rick J, et al. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 2015;14:1002-9.
16. Keller MF, Saad M, Bras J, et al. Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet 2012;21:4996-5009.
17. Ritz B, Rhodes SL, Bordelon Y, et al. α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS ONE 2012;7: e36199.
18. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
19. Selikhova M, Fedoryshyn L, Matviyenko Y, et al. Parkinsonism and dystonia caused by the illicit use of ephedrone-a longitudinal study. Mov Disord 2008;23:2224-31.
20. Gardner RC, Burke JF, Nettiksimmons J, et al. Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol 2015;77:987-95.
21. McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013;136:43-64.
22. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-8.
23. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 2012;27:947-57.
24. Simon KC, Eberly S, Gao X, et al. Mendelian randomization of serum urate and Parkinson disease progression. Ann Neurol 2014;76:862-8.
25. Chaudhuri KR, Healy DG, Schapira AHV, et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45.
26. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010;25:2493-500.
27. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74.
28. Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015;14:57-64.
29. Adams-Carr KL, Bestwick JP, Shribman S, et al. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015.
30. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003;18:364-72.
31. Iranzo A, Molinuevo JL, Santamaría J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572-7.
32. Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 2015;77:830-9.
33. Mahlknecht P, Iranzo A, Hogl B, et al. Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 2015;84:654-8.
34. Postuma RB, Gagnon J-F, Bertrand J-A, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015;84:1104-13.
35. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 2015;30:1600-11.
36. Postuma RB, Lang AE, Gagnon JF, et al. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012;135:1860-70.
37. Maetzler W, Domingos J, Srulijes K, et al. Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord 2013;28:1628-37.
38. Pasluosta CF, Gassner H, Winkler J, et al. An emerging era in the management of Parkinson's disease: wearable technologies and the internet of things. IEEE J Biomed Health Inform 2015;19:1873-81.
39. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med 2010;51:596-609.
40. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009;132:2970-9.
41. Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-35.
42. Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10:797-805.
43. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome study. Neurology 2014;83:1739-46.
44. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008;7:417-24.
45. Orimo S, Suzuki M, Inaba A, et al. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012;18: 494-500.
46. Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007;17:24-30.
47. Sakakibara R, Tateno F, Kishi M, et al. MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat Disord 2014;20:267-73.
48. Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat Disord 2014;20:S99-103.
49. Qiang JK, Wong YC, Siderowf A, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 2013;74:119-27.
50. Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 2014;85:1065-75.
51. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010;5:e12728.
52. Beach TG, Adler CH, Sue LI, et al., Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
53. Visanji NP, Marras C, Hazrati LN, et al. Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord 2014;29:444-50.
54. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015;30:1351-60.
55. Beach TG, Adler CH, Dugger BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 2013;72:130-6.
56. Donadio V, Incensi A, Leta V, et al. Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014;82:1362-9.
57. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011;68:932-7.
58. Gaenslen A, Wurster I, Brockmann K, et al. Prodromal features for Parkinson's disease-baseline data from the TREND study. Eur J Neurol 2014;21:766-72.
59. Baig F, Lawton M, Rolinski M, et al. Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. Mov Disord. Published Online First: 14 Jul 2015. doi:10.1002/mds.26281
60. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry 2013;85:31-7.